In our study, prognosis in patients aged <50 years with metastatic NSCLC was very poor but notably improved in the 59 patients (33%) who had a targeted therapy (anti-EGFR/ALK/ROS1 TKI) option (mOS 28.7 vs. 6.6 m). This evidence concerns the gene ALK and non-small cell lung carcinoma.